Rhythm projects 2024 revenues of $580-$590 million but no profits, raising questions about long-term viability. Read more about IRTC stock and its challenges.
Advamed’s largest — featured an appearance by the device center’s new acting director and sessions on AI, clinical trial diversity and the FDA’s contentious LDT rule.
Bluefin is Sycurio's solution partner for PCI-validated point-to-point encryption (P2PE) devices, reducing a customer's PCI DSS compliance burden by more than 70% and PCI control scope reduction at ...